Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.

European journal of clinical pharmacology - 1 Jan 1997

Spigset O, Granberg K, Hägg S, Norström A, Dahlqvist R

Abstract excerpt

OBJECTIVE: The purpose of this study was to investigate whether the disposition of fluvoxamine is associated with the CYP2D6 and CYP2C19 phenotype polymorphisms. METHODS: The serum concentration of fluvoxamine was followed for 48 h after oral administration of a single dose of 50 mg fluvoxamine to five poor metabolizers of the CYP2D6 test drug dextromethorphan, five poor metabolizers of the CYP2C19 test drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 Enzyme System

Share to Dextromethorphan

Share to Mixed Function Oxygenases

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 9174682
DOI: 10.1007/s002280050261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.PMID 9174682Read ↗

Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.Semantic proximity Read ↗

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.Semantic proximity Read ↗

Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder.Semantic proximity Read ↗

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.Semantic proximity Read ↗

Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.Semantic proximity Read ↗

CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.Semantic proximity Read ↗

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.Semantic proximity Read ↗

Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.Semantic proximity Read ↗

Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease.Semantic proximity Read ↗

Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.Semantic proximity Read ↗

Polymorphisms in the 5-Hydroxytryptamine 2A Receptor and CytochromeP4502D6 Genes Synergistically Predict Fluvoxamine-Induced Side Effects in Japanese Depressed PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.